Premium
Semi‐mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer
Author(s) -
Chudasama V L,
Schaedeli Stark F,
Harrold J M,
Tibbitts J,
Girish S R,
Gupta M,
Frey N,
Mager D E
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.153
Subject(s) - trastuzumab , pharmacokinetics , trastuzumab emtansine , antibody drug conjugate , metastatic breast cancer , medicine , pharmacology , breast cancer , population , monoclonal antibody , oncology , transdermal , cancer , drug , antibody , immunology , environmental health
Trastuzumab emtansine (T‐DM1) is an antibody–drug conjugate (ADC) composed of multiple molecules of the antimicrotubule agent DM1 linked to trastuzumab, a humanized anti–human epidermal growth factor receptor 2 (HER2) monoclonal antibody. Pharmacokinetics data from phase I ( n = 52) and phase II ( n = 111) studies in HER2‐positive metastatic breast cancer patients show a shorter terminal half‐life for T‐DM1 than for total trastuzumab (TTmAb). In this work, we translated prior preclinical modeling in monkeys to develop a semi‐mechanistic population pharmacokinetics model to characterize T‐DM1 and TTmAb concentration profiles. A series of transit compartments with the same disposition parameters was used to describe the deconjugation process from higher to lower drug‐to‐antibody ratios (DARs). The structure could explain the shorter terminal half‐life of T‐DM1 relative to TTmab. The final model integrates prior knowledge of T‐DM1 DARs from preclinical studies and could provide a platform for understanding and characterizing the pharmacokinetics of other ADC systems. Clinical Pharmacology & Therapeutics (2012); 92 4, 520–527. doi: 10.1038/clpt.2012.153